Publication

Article

Oncology Nursing News
February 2011
Volume 5
Issue 1

Ovarian Cancer Screening Not Very Effective

Author(s):

Screening for ovarian cancer offers limited value, especially when accounting for the disease's biological diversity.

Screening for ovarian cancer offers limited value, especially when accounting for the disease's biological diversity, according to a study from the Duke Cancer Institute. Research has shown that ovarian cancer is not a single disease as was previously thought, but rather comprises at least 2 subtypes of varying aggression. The Duke researchers’ computer model predicted that ovarian cancer screening (CA125 and ultrasound) of women aged >50 years would reduce mortality rates by 15% in the single-disease concept and 11% in the 2-subtype model. The percentages vary because the single-disease screening does not account enough for the more aggressive, deadlier tumors. The researchers suggested that, in light of the paltry numbers, preventive measures beyond screening are needed to help control ovarian cancer.

Related Videos
Angeles A. Secord, MD, MHSc
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Kimberly Cannavale, MPH
Kimberly Cannavale, MPH
Amma Asare, MD, PhD
Matthew Powell, MD
Laura J. Chambers, DO
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Maurie Markman, MD